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Introduction
Lung cancer is the second most common cancer and the leading cause of cancer death in industrialized countries (1, 2) . Non-small cell lung cancer is a heterogeneous disease, with adenocarcinomas (AC) and squamous cell carcinomas the most common subtypes (3) . These histological subtypes have diverse clinical outcomes, different treatments, revealing heterogeneity in both disease aggressiveness and underlying molecular alterations (4) .
Complete resection gives the highest probability of long-term remission and cure. Even among surgically-treated early stage patients, the 5-year survival rate is only 52% (2) . Postoperative adjuvant chemotherapy is the standard of care for resected stage II and III and provides an absolute benefit of 4-5% in 5-year survival rates (5, 6) . However a subset of stage I patients also have poor prognosis and it is important to identify these high-risk patients who might benefit from an additional therapeutic intervention.
Molecular biomarkers incorporated with clinicopathological factors might improve
NSCLC patient management (7) . KRAS and TP53 mutations (8, 9) , and gene-expression signatures can classify surgically-resected patients with different outcomes (10) . MiRs are small non-coding regulatory RNAs that are upstream regulators of gene-expression and contribute to cancer development and progression by acting as oncogenes or tumor suppressor genes (11) (12) (13) . MiRs are promising biomarkers and involved in regulating diverse biological processes such as cell proliferation, apoptosis, adhesion, migration, invasion and angiogenesis.
MiR-34b and miR-34c, two members of the miR-34 family, are encoded by a bicistronic transcript from chromosome 11q23 (14) . Their expression may be induced by TP53 in response to DNA damage or cell stress (15) as well as regulated by DNA methylation. The promoter regions of miR-34b/c are hypermethylated in several tumor types resulting in silencing of miR34b/c expression (16) (17) (18) (19) (20) (21) . MiR-34b/c methylation was prognostic in NSCLC stage I patients (22) , but this result has not been validated in an independent cohort. In addition, miR-34 family acts as a tumor-suppressor among different tumor types, inducing a less aggressive phenotype (16, 20, 23, 24) , however the functional role of miR-34b/c has not been examined in lung AC.
In the present study, we sought to determine the role of miR-34b/c methylation and expression in lung AC cell lines and primary tumors, the relationship to patient prognosis in two independent cohorts of early stage resected lung AC and the functional impact of miR-34b/c ectopic expression on lung AC invasion and proliferation. Informed consent, approved by the respective Institutional Review Board, was obtained and specimens collected, immediately frozen and stored at -80°C. Regions containing >70% tumor cellularity were used for nucleic acid isolation. Patients receiving preoperative radiation or chemotherapy were not included. Clinical data was retrospectively collected and all cases were staged according to the revised 7 th TNM classification and provided in Suppl. Table S1 .
Material and Methods

Tissue samples
Patients from the University of Michigan were older and included more females and formersmokers than the Bellvitge Hospital set. These differences reflected specific patterns of lung AC according to patient's site (25) .
Lung cancer cell lines
Fifteen human lung AC cell lines (SK-LU-1, NCI-H2228, NCI-H1838, NCI-H1563, NCI-H2347, NCI-H1395, Calu-3, A549, NCI-H2087, NCI-H1299, NCI-H838, NCI-H23, NCI- HCC4006 and HCC827) were purchased from American Type Culture Collection (Manassas, VA) and authenticated by genotyping using the Identifier Plus kit (Applied Biosystems). All cells were maintained in RPMI-1640 (except Calu-3 and A549, which used Eagle's minimum essential medium and DMEM-F12 medium respectively), and supplemented with 10% FBS, 1%
Gibco® Antibiotic-Antimycotic (Life Technologies) in an atmosphere containing 5% CO 2 at 37°C.
Cell line mutational status was obtained from the IARC TP53 database (26) and Sanger Institute Catalogue of Somatic Mutations In Cancer web site (27) with nine harboring TP53 mutations or TP53 deletion and listed in Suppl. Table S2 .
Chemicals and demethylation treatment of lung AC cell lines
Stock solutions of 1mM cis-diammine-dichloroplatinum (Sigma-Aldrich), 1mM pemetrexed (Lilly), 10mM erlotinib hydrochloride (Selleckchem) and 25mM 5-aza-2'-desoxycytidine (5-aza-dC, Sigma-Aldrich) were stored at -20°C and freshly dissolved in culture medium before use. SK-LU-1, NCI-H2228, NCI-H1838, NCI-H23 and HCC4006 cells were seeded in 6 well plates, cultured for 24 hours, and treated with 0.5 μmol/L of 5-aza-dC for 5 days in triplicate, replacing drug-containing medium daily. The cells were subjected to DNA and RNA isolation for direct sequencing and miR-34b/c quantification, respectively.
Bisulfite genome sequencing (BGS)
DNA was isolated using the proteinase K/phenol extraction method. Bisulfite conversion was carried out using 1 μg of DNA using an EZ-DNA Methylation Gold kit (Zymo Research).
The PCR was performed using Immolase DNA Polymerase (Bioline) and the following primers:
5'-GGTTGGGAATTGAAGTTTG-3' (F) and 5'-TTAATAATTATAACCACCACAATACAA-3' (R).
The reactions were cycled at 95°C for 10 minutes, then 30 cycles of 30 seconds (sec) at 95°C, 30 sec at 58°C and 30 sec at 72°C, including a final extension step for 15 minutes. PCR products were gel-purified using QIAquick Gel Extraction kit (Qiagen) and cloned into pCR Samples were classified as methylated when the estimated methylation value was higher than 5%.
RNA isolation and miR and mRNA quantification in cell lines and tumors
Total RNA was isolated using miRNeasy kits (Qiagen) following manufacturer's instructions. Expression of mature miR-34b and miR-34c was assessed by real-time RT-PCR (qRT-PCR) using TaqMan Micro-RNA assays (Applied Biosystems) and the 7900 HT-Fast RealTime PCR System (Applied Biosystems). Expression of reported miR-34b/c targets (AXL, BCL2, HMGA2, MET, NOTCH1 and NOTCH2) was assessed by qRT-PCR in miR-34b/c transfected cells (14, 29) . cDNA was prepared from total RNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems) following manufacturer's instructions and using Power SYBR Green and the 7900 HT-Fast Real-Time PCR System (Applied Biosystems). Primers, designed using Primer-BLAST (30) , are shown in Suppl. Table S3 . Data were analyzed using the SDS 2.2.2 software (Applied Biosystems) with threshold setting at 0.2 and manual baseline from 3 to 18 cycles. Relative quantification was performed by using the 2 -ΔΔCt method, using endogenous RNU48 and ß-Actin expression as controls for miR and mRNA quantification, respectively.
Plasmid construction and stable transfection
The miR-34b/c was subcloned into pSilencer 4.1-CMV puro Expression Vector (Ambion)
containing the flanking regions of the mature miR-34b/c (16) . Ten µg of the constructed plasmid and the empty vector were introduced into H1838 and SK-LU-1 cells using FUGENE 6
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Cell proliferation assay
Empty vector and miR-34b/c stably transfected H1838 and SK-LU-1 cells were plated in 96-well plates for 24 hours. Chemosensitivity was tested by treating miR-34b/c stably transfected cells with cisplatin, pemetrexed and erlotinib for 48 hours or with drug-free medium.
The cell proliferation and viability was assessed using 10μl/well of WST-1 reagent (Roche).
Absorbance at 450 nm and reference at 630 nm were measured with an automated plate reader (ELx808 Bio-Tek) at different time-points. Relative proliferation rates were calculated as a percentage of the initial T 0 reading within each sub-cell line.
Apoptosis assay
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Wound-healing assay
Empty vector and miR-34b/c stably transfected cells were grown to confluence. A wound was made through the monolayer using a p20 tip and measurements taken over time to calculate the migration rate according to the equation: percentage wound healing = ((wound length at 0 h) -(wound length at 4, 6, 20 or 27 h)) / (wound length at 0 h) x 100. Two independent experiments were performed.
Trans-well invasion assay
Cancer cells were re-suspended in media without growth factors then seeded at 25,000 cells per well into matrigel-coated (BD Matrigel), growth-factor-reduced, invasion chambers (8 μm pore size, BD Biosciences). The bottom chamber contained 20% FBS media as chemoattractant and incubated overnight in a humidified incubator at 37°C, 5% CO 2 atmosphere. The top non-invading cells were removed with a cotton swab moistened with medium and the lower surface of the membrane was stained with Diff-Quick Stain Set (Siemens). The number of cells migrating to the basal side of the membrane was visualized with an Olympus microscope at 20x magnification. Pictures of five random fields from replicate wells were obtained and the number of cells stained quantified relative to the migration of cells through the uncoated membrane.
Statistical analysis
Differences between both cohorts used in the methylation analysis were calculated with Student's t-test and Fisher's exact tests. Non-parametric tests were used for differences in miR- plotted using the Kaplan-Meier method and survival differences were assessed using the logrank test. The univariate and multivariate Cox proportional hazards model were used to assess survival results. Disease-free survival (DFS) was measured from the date of surgery to the time of recurrence, death or censoring. Overall survival (OS) was measured from date of surgery to the time of death or censoring. 
Results
MiR
in Fig. 2A , the cells with lowest expression contained miR-34b/c promoter methylation and TP53 mutation.
The miR-34b/c expression was significantly increased from 29-to >500 fold when cells with hypermethylated miR-34b/c promoter (SK-LU-1, H2228 and H1838) were treated with 5-aza-2'-deoxycytidine (5-aza-dC) for 5 days (Suppl . Fig. S2A) . A relative change in the methylation level was detected by direct bisulfite sequencing in cell lines treated with 5-aza-dC (Suppl. Fig S2B) .
MiR-34b/c methylation and underexpression are a frequent event in lung AC tumors
MiR-34b/c methylation was assessed by MCA in 140 lung AC tumors and 10 nonmalignant lung tissues. Fifty-nine tumors (42%) showed more than 5% DNA methylation (Suppl. 
death (P = 0.019). Tumors from patients with a smoking history had a trend of higher levels of miR-34b/c methylation.
We determined the correlation between miR-34b/c expression with clinical and molecular variables for the 49 cases analyzed (Suppl . Table S4 ). Interestingly, lower expression of miR-34b was detected among smokers compared to nonsmokers (P = 0.025).
Tumors harboring TP53 mutation had a trend of lower miR-34b and 34c expression (P = 0.043 and 0.060, respectively). A significant difference in the expression of miR-34b/c was observed in primary tumors when classified based upon the promoter methylation status and the TP53 mutational status (P = 0.0007 and 0.001, respectively, Fig. 2B ). MiR-34b/c methylation appears to be the predominant mechanism of regulation of miR-34b/c expression in cooperation with TP53 function. Indeed, tumors with methylated miR-34b/c consistently expressed low levels of miR-34b/c even when TP53 was not mutated. Of note, higher miR-34b/c expression was associated with EGFR mutation (P = 0.007 and 0.013, respectively, Suppl. Table S4 ). MiR34b/c expression was not associated with outcome as previously reported by others (31).
MiR-34b/c methylation as independent prognostic marker in early stage resected lung AC
We determined the prognostic value of miR-34b/c methylation in the training set and we found that patients with higher AUC for miR-34b/c methylation (top third) had a significantly shorter DFS (median: 28.5 months) compared to patients with low AUC levels (bottom two thirds) (median: not reached, Log-rank test P = 0.016, Fig. 3A) . We used two thirds cut-off (AUC = 1.34, estimated methylation = 20%) instead of the median, because it provided a higher percentage of events within the group of high level of DNA methylation. In the multivariate Cox model, higher levels of miR-34b/c methylation (top third) were independently associated with shorter DFS (HR = 3.04, 95% CI 1.26 -7.03, P = 0.013) as compared to low-medium levels, after adjusting for age, sex and disease stage. In the test set, high (top third) also had a shorter DFS (median: 18.6 months) compared to patients with low AUC (bottom two thirds) (median: not reached, Log-rank test P = 0.005, Fig. 3B ). In the multivariate analysis, high levels of miR-34b/c methylation (top third) were associated with shorter DFS (HR = 2.05, 95% CI 1.09 -3.84, P = 0.025).
When the survival analysis was carried out using the whole study population (n = 140), miR-34b/c methylation not only was associated with shorter DFS, but also with shorter OS (Kaplan-Meier plots are shown in Suppl. Fig. S4 ). In the multivariate Cox regression analysis, higher levels of miR-34b/c methylation (top third) was independently associated with a shorter DFS (HR = 2.16, 95% CI 1.32 -3.52, P = 0.002, Table 2 ) as compared to low to medium levels (bottom two-thirds). MiR-34b/c remained an independent prognostic marker when considered as continuous variable in the Cox regression (Suppl . Table S5 ). Higher levels of miR-34b/c (top third) were also independently-associated with shorter OS (HR = 1.79, 95% CI 1.07 -3.02, P = 0.027, Suppl. Table S6 ) as compared to low-medium levels. Remarkably, methylation of miR34b/c was also a prognostic marker for stage I patients and patients with high AUC for miR34b/c had a shorter DFS (median: 43.1 months) as compared to those with low to medium levels (median: not reached, Log-rank test P = 0.009, Suppl. Fig. S5 ).
MiR-34b/c ectopic expression reduced cell proliferation, migration and invasion
Two cell lines with low levels of miR-34b/c (H1838 and SK-LU-1) were transfected with miR-34b/c precursors that mimics endogenous miRs, or alternatively with empty vector.
Expression of miR-34b/c determined by qRT-PCR in the stable transfectants was significantly higher compared to empty vector and parental cells (Suppl . Fig. S6A ). Several genes reported as putative targets of miR-34b/c were examined and a significant reduction of the transcript levels were found for AXL, BCL-2, HMGA2, MET, NOTCH1 and NOTCH2 in both transfected cell lines (Suppl. Fig. S6B) . At the protein level significant reduction of MET expression was observed (Suppl. Fig. S6C ). Cells expressing miR-34b/c showed a significantly lower proliferation rate as compared to empty vector (P < 0.001, Fig. 4A) . Accordingly, stable transfection with miR-34b/c mimics resulted in significantly increased PARP cleavage (Suppl . Fig. S7A) . We treated the stable cell lines with cisplatin (CDDP), pemetrexed or erlotinib, all of which are currently used for treating lung AC. A modest sensitization effect to CDDP was observed after restoring miR-34b/c expression in SK-LU-1 cells (Suppl . Fig. S7B ). Migration and cell invasion was significantly suppressed in miR-34b/c stable transfectants of SK-LU-1 (Fig. 4B, 4C and Suppl. Fig. S8 ) as compared to empty vector or parental cells.
In summary, the restoration of miR-34b/c expression in lung AC lines can reduce cell proliferation, cell migration and invasion, conferring a less aggressive phenotype. Re-expression thus might be a novel potential therapeutic strategy in patients expressing low levels of miR34b/c.
Discussion
MiRs play an important role in tumorigenesis and cancer progression. The discovery of their regulatory function has added a new level of complexity in our understanding of cancer genetics (32) . Interestingly, miR expression is often widely down-regulated in cancer cells relative to normal tissues (33) , and forced reduction of global miR expression promotes transformation (34) . MiR expression is deregulated in human cancer, including NSCLC and several regulatory mechanisms have been identified: DNA copy abnormalities (35), mutation (36) , failure of post-transcriptional regulation (37) , regulation by transcription factors (38) , and a defective miR biogenesis pathway (34) . Additional epigenetic mechanisms such as methylation of the 5' regulatory regions associated with specific miR down-regulation in tumors were observed (16, 39, 40) . The miR-34 family consists of miR-34a, located at the chromosome 1, and miR-34b and miR-34c, located at the chromosome 11 as a bicistronic cluster and primarily expressed in nontumoral lung (23) . The putative promoter of miR-34b/c resides 4.5 kb upstream of the miRcoding sequence and includes a dense CpG island and the starting transcription site of BTG4 gene (21) . We found that hypermethylation of miR-34b/c is frequent in lung AC tumors and cell lines (40-46%), which is similar to the frequency reported previously by other groups in NSCLCs (22) . Interestingly, we observe patients with higher levels of miR-34b/c methylation show a worse outcome. A recent study reported that miR-34b/c methylation might be prognostic for stage I NSCLC patients (22) . In this study, DNA methylation was assessed by MethylationSpecific PCR from formalin-fixed paraffin tissue samples. We used frozen samples and DNA methylation was assessed using MCA, which achieved an excellent analytical sensitivity. We feel that MCA is a useful technique for detecting and estimating DNA methylation by simultaneous assessment of multiple CpG residues, rendering the technique less vulnerable to the behaviour of specific residues. When analyzing other markers using MCA, it is important to determine the analytical sensitivity for any specific gene to define a cut-off for classifying the samples as either methylated or unmethylated. While focusing on lung AC, we validated the prognostic value of miR-34b/c methylation in an independent cohort of these patients.
According to previous data (23) , global association between TP53 mutational status and miR-34b/c expression was not found in lung AC lines. Indeed, although miR-34b/c are bona fide transcriptional targets of TP53 and their promoters contain TP53-canonical binding sites, miR-34 family appeared to be not necessary for TP53 function using a miR-34 deficient mouse (41) .
A potential interaction between DNA methylation status and TP53 status was found in lung AC cell lines and primary tumors. In addition, the restoration of miR-34b/c expression with 5-aza-dC suggests that DNA methylation plays a role in the transcriptional regulation of these miRs in lung AC cells. 
Interestingly, miR-34b expression was higher in nonsmoking patients and both miRs were significantly overexpressed in EGFR mutant cell lines and primary tumors. Although nonsmoking patients had lower levels of miR-34b/c expression as compared to smokers, we did not find a significant correlation between tobacco use history and DNA methylation. Similarly, during bronchial carcinogenesis of squamous cell carcinomas, expression of miR-34c progressively was reported to decrease from normal epithelium of nonsmokers to invasive bronchial lesions of smokers (42) .
The role of miR-34b/c expression as a prognostic marker is controversial. Landi et al (43) found that miR-34b/c expression measured by microarray technology was associated with outcome in surgically-resected lung NSCLC patients. However miR-34b/c measured by qRT-PCR was not prognostic in a large cohort of early stage NSCLC (31) . In our study, we could not find an association between miR-34b/c expression and outcome potentially due to the limited number of cases analyzed.
We used stable transfectants expressing miR-34b and 34c to study the pathogenic role of these miRs in lung AC lines. Using this in vitro model, we found that the restoration of miR34b/c expression suppressed cell proliferation, migration and invasiveness. These findings suggest that these miRs might act as a tumor suppressor in lung AC, which is consistent with its role in other human cancers (20, 24, 44, 45) .
MiR-34b/c restoration did not considerably modify the sensitivity to CDDP, pemetrexed or erlotinib in lung AC lines. Correspondingly, miR-34b/c expression was previously not found to have a predictive effect on survival in lung cancer patients treated with adjuvant chemotherapy after tumor resection (31) . However, miR-34c appears to be significantly overexpressed in erlotinib-sensitive NSCLC cell lines (46) and was associated with a signature predictive for response to erlotinib. In our study miR-34b/c transfectants did not show higher sensitivity to erlotinib (data not shown).
Several strategies have been proposed to restore the function of miRs with tumor suppressor properties that are down-regulated in cancer (47) , for example DNA demethylating agents and histone deacetylase inhibitors, which have demonstrated anti-tumor activity in chemo-refractory NSCLC (48) . However a limitation of this strategy is that these agents lack specificity. A more promising strategy may be miR replacement therapy using delivery vehicles (49, 50) , which are able to restore loss of function activity and to reactivate cellular pathways in cancer that drive a therapeutic response.
In conclusion, our findings show that miR-34b/c is frequently inactivated by promoter DNA methylation in lung AC and restoration of miR-34b/c expression induces a less aggressive and invasive phenotype. In addition, miR-34b/c methylation might be an independent prognostic marker in early stage lung AC and is potentially useful for selecting a subset of stage I tumors with higher risk of recurrence or death after lung resection that would benefit from an additional therapeutic intervention. MiR replacement therapy might be a potential strategy for treating those tumors with hypermethylated miR-34b/c, although further investigation in this area is needed. 
